EGFR and non-small cell lung carcinoma: In a phase III trial conducted in China, the use of almonertinib as the first-line treatment was well-tolerated and showed a significant increase in PFS: 19.3 months with almonertinib versus 9.9 months with gefitinib and duration of response (18.1 months versus 8.3 months) for advanced NSCLC patients with EGFR mutations (deletion of exon 19 or L858R substitution) [169].